Novel antibacterial compounds addressing resistance: patent disclosures 2002 – 2005

Bibliography

• FOX JL: Concerns raised over declining antiinfectives R&D. Nat. Biotechnol. (2003) 21:1255–1256.
   PubMedGoogle Scholar
• SHLAES DM: The abandonment of antibacterials: why and wherefore? Cuff. Opin. PharmacoL (2003) 3:470–473.
   PubMed Web of Science ®Google Scholar
• POWERS JH: Antimicrobial drug development - the past, the present and the future. Clin. Microbiol Infect. (2004) 10\(Supp1.4):23–31.
   Google Scholar
• NORMARK BH, NORMARK S: Evolution and spread of antibiotic resistance. (2002)1 Intern. Med. 252: 91–106.
   Google Scholar
• WALSH FM, AIVIYES SGB: Microbiology and drug resistance mechanisms of fully resistant pathogens. Curr. Opin. MicrobioL (2004) 7:439–444.
   PubMedGoogle Scholar
• FLUIT AC, SCHMITZ F-J: Resistance integrons and super-integrons. (2004) Clin. MicrobioL Infect 10:272–288.
   Google Scholar
• FRIDKIN SK, HILL HA, VOLKOVA NV et al.: Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg. Infect. Dis. (2002) 8:697–701.
   PubMed Web of Science ®Google Scholar
• LOWY FD: Antimicrobial resistance: the example of Staphylococcus aureus. j Clin. Invest. 111:1265-1273.
   Google Scholar
• KARCHMER AW: Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US - an update. Clin. Infect. Dis. (2004) 39\(Suppl. 3):5142–150.
   Google Scholar
• ZHANEL GG, HOMENUIK K, NICHOL K et al.: The glycylcyclines: a comparative review with the tetracyclines. Drugs. (2004) 64:63–88.
   PubMed Web of Science ®Google Scholar
• SPIERS KM, ZERVOS MJ: Telithromycin. Expert Rev. Anti Infect. Ther. (2004) 2:685–693.
   PubMedGoogle Scholar
• ROGERS BL: Bacterial targets to antimicrobial leads and development candidates. Cuff. Opin. Drug Discov. Devel (2004) 7:211–222.
   PubMedGoogle Scholar
• ALEKSHUN MN: New advances in antibiotic development and discovery. Expert Opin. Investig. Drugs (2005) 14(2):117–134.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the latest developmentsin antibacterials.
   Google Scholar
• DRLICA K, ZHAO X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. (1997) 61:377–392.
   PubMed Web of Science ®Google Scholar
• WANG JC: Cellular roles of DNA topoisomerases: a molecular perspective. (2002) Nat. Rev. Mol Cell Biol. 3: 430–440.
   Google Scholar
• WILLIAMS NL, HOWELLS AJ, MAXWELL A: Locking the ATP-operated clamp of DNA gyrase: probing the mechanism of strand passage. J. MoL Biol (2001) 306:969–984.
   PubMedGoogle Scholar
• HIGGINS PG, FLUIT AC, SCHMITZ FJ: Fluoroquinolones: structure and target sites. Curr. Drug Targets (2003) 4:181–190
   PubMed Web of Science ®Google Scholar
• HEDDLE J, MAXWELL A: Quinolone binding pocket of DNA gyrase: Role of GyrB. Antimicrob. Agents Chemother. (2002) 46:1805–1815.
   PubMed Web of Science ®Google Scholar
• ROBBINS MJ, SHACKCLOTH J, DENCER C, WILLIAMS L, BRYSKIER A, FELMINGHAM D: Comparative in vitro activity ofAVE6971, a novel inhibitor of DNA topoisomerase IV against Staphylococcus aureus (SA). 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (2004) F–1949.
   Google Scholar
• TRAN T, ELLSWORTH E, STIER M et al.: Synthesis and structural-activity relationships of 3-hydroxyquinazoline-2,4-dione antibacterial agents. Bioorg. Med. Chem. Lett. (2004) 14:4405–4409.
   PubMed Web of Science ®Google Scholar
• GRILLOT A, STAMOS D, GROSSMAN T et al.: A new class of dual targeting inhibitors of GyrB and ParE. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA (2004) F–1951.
   Google Scholar
• MANI N, STAMOS D, GRILLOT J et aL: Dual-targeting of bacterial Type II topoisomerases by a novel class of antibacterial compounds. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotheraphy, Washington DC, USA (2004) F–1952.
   Google Scholar
• ADAMS JM: On the release of the formylgroup from nascent protein. J. MoL Biol (1968) 33:571–589.
   PubMed Web of Science ®Google Scholar
• MEINNEL T, LAZENNEC C, VILLOING S, BLANQUET S: Structure-function relationships within the peptide deformylase family. Evidence for a conserved architecture of the active site involving three conserved motifs and a metal ion. J. MoL Biol. (1997) 267:749–761.
   Google Scholar
• APFEL CM, LOCHER H, EVERS S et al.: Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimocrob. Agents Chemother. (2001) 45(4):1058–1064.
   PubMed Web of Science ®Google Scholar
• BOULAROT A. GIGLIONE C, ARTAUD I, MEINNEL T: Structure-activity relationship analysis and therapeutic potential of peptide deformylase inhibitors. Curr. Opin. Investig. Drugs (2004) 5(8):809–822.
   PubMedGoogle Scholar
• JAIN R, CHEN D, WHITE RJ, PATEL DV YUAN Z: Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr. Med. Chem. (2005) 12:1607–1621.
   PubMedGoogle Scholar
• GRONOW S, BRADE H: Lipopolysaccharide biosynthesis: which steps do bacteria need to survive? Endotoxin Res. (2001) 7:3–23.
   Google Scholar
• TRENT MS: Biosynthesis, transport, and modification of lipid A. Biochem Cell Biol. (2004) 82:71–86.
   PubMedGoogle Scholar
• HERNICK M, FIERKE CA: Zinc hydrolases: the mechanisms of zinc-dependent deacetylases. Arch Biochem. Biophys. (2005) 433:71–84.
   PubMed Web of Science ®Google Scholar
• WHITTINGTON DA, RUSCHE KM, SHIN H, FIERKE CA, CHRISTIANSON DW: Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis. Proc. Natl Acad. Sci. USA (2003) 100(14):8146H8150.
   Google Scholar
• GOGGINS BE, LI X, MCCLERREN AL, HINDSGAUL 0, RAETZ CRH, ZHOU P: Structure of the LpxC deacetylase with a bound substrate-analog inhibitor. Nat. Struct. Biol (2003) 10(8):645–651.
   PubMedGoogle Scholar
• SUTTON MD, WALKER GC: Managing DNA polymerases: coordinating DNA replication, DNA repair, and DNA recombination. Proc. Natl. Acad. Sci. USA (2001) 98:8342–8349.
   PubMed Web of Science ®Google Scholar
• LEMON K, MORIYA S, OGASAWARA N, GROSSMAN AD: Chromosome replication and segregation. In: Bacillus subtilis and its closest relatives. Al Sonenshein (Ed.), ASM Press (2002)73–86.
   Google Scholar
• ERIANI G, DELARUE M, POCH 0, GANGLOFF J, MORAS D: Partition of t-RNA synthetases into two classes based on mutually exclusive sets of sequence motifs. Nature (1990) 347:203–206.
   PubMed Web of Science ®Google Scholar
• PARENTI MA, HATFIELD SM, LEYDEN JJ: Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin. Pharm. (1987) 6:761–770.
   PubMedGoogle Scholar
• WHITE SW, ZHENG J, ZHANG YM, ROCK CO: The structural biology of Type II fatty acid biosynthesis. Ann. Rev. Biochem. (2005) 74:791–831.
   PubMed Web of Science ®Google Scholar
• PAYNE DJ, WARREN PV, HOLMES DJ, JI Y, LONSDALE JT: Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. Drug Discov. Today (2001) 6:537–544.
   PubMedGoogle Scholar
• BRICKNER SJ, GAIKEMA JJ, ZURENKO GE, GREENFIELD LJ, MANNINEN PR, ULANOWICZ DA: N-acyl 3-alkylidenyl- and 3-alkylazetidin-2-ones: a new class of monocyclic 0-lactam antibacterial agents. 1. Structure-activity relationships of 3-isopropylidene and 3-isopropyl analogs./ Antibiot. (1992) 45(2):213–226.
   Google Scholar
• BRICKNER SJ, GAIKEMA JJ, GREENFIELD LJ, ZURENKO GE, MANNINEN PR: N-acyl 3-alkylidenyl-and 3-alkyl azetin-2-ones: a new class of monocyclic 0-lactam antibacterial agents. 2. Synthesis and structure-activity relationships of heteroatom substituted 3-isopropylidene and 3-isopropyl analogs. Bioorg. Med. Chem. Lett. (1993) 3(11):2241–2246.
   Google Scholar
• EL ZOEIBY A. SANSCHAGRIN F, LEVESQUE RC: Structure and function of the Mur enzymes: development of novel inhibitors. MoL MicrobioL (2003) 47(1): 1–12.
   PubMed Web of Science ®Google Scholar
• LI X-Z, NIKAIDO H: Efflux-mediated drug resistance in bacteria. Drugs (2004) 64(2): 159–204.
   PubMedGoogle Scholar
• LI Q, LEE JY, CASTILLO R et al.: NB2001, a novel antibacterial agent with broad-spectrum activity and enhanced potency against 0-lactamase producing strains. Antimicrob. Agents Chemother. (2002) 46(5):1262–1268.
   PubMed Web of Science ®Google Scholar
• STONE GW, ZHANG Q, CASTILLO R et al.: NB2001 and NB2030, novel antibacterial agents activated by 0-lactamases. Antimicrob. Agents Chemother. (2004) 48(2):477–483.
   PubMed Web of Science ®Google Scholar
• PAYNE DJ, HOLMES DJ, ROSENBERG M: Delivering novel targets and antibiotics from genomics. Curr. Opin. Investig. Drugs (2001) 2:1028–1034.
   PubMedGoogle Scholar
• ROGERS BL: Bacterial targets to antimicrobial leads and development candidates. Curr. Opin. Drug Discov. DeveL (2004) 7:211–222.
   PubMedGoogle Scholar